In compliance with Regulation 30 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), Rossari Biotech has informed that at the meeting of the Board of Directors of the Company, which commenced at 10:30 AM and concluded at 11:20 AM today i.e. December 18, 2025, the Board of Directors have approved the following: Incorporation of wholly owned subsidiary in Republic of Singapore Incorporation of a wholly owned subsidiary in Republic of Singapore with an initial investment of upto USD ~10 million, in tranches. The Wholly Owned Subsidiary in Republic of Singapore is a further step of the Company towards increasing its global presence. The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/ CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 in relation to the said subsidiary are set out under Annexure - A. The aforesaid information will also be available on Company’s website at www.rossari.com.
The above information is a part of company’s filings submitted to BSE.
